Background {#Sec1}
==========

Traditionally, tobacco and alcohol use have subscribed to be the primary risk factors for oropharyngeal squamous cell carcinoma (OPSCC). However, the past decade has seen a rapid increase in the incidence of human papillomavirus (HPV) related oropharyngeal cancers in developing countries \[[@CR1]--[@CR4]\]. Molecular and epidemiologic studies suggest that HPV-positive oropharyngeal cancers comprise a distinct disease entity that has a higher survival and better response to treatment \[[@CR5]--[@CR8]\]. Although survival is the fundamental goal in treating oropharyngeal cancer patients, their functional and quality of life (QOL) outcomes are becoming a primary concern of the patients and their health care providers. The issue of these outcomes after surgical treatment has received considerable critical attention.

The optimal treatment of advanced stage OPSCC has been a subject of debate for several years. In population based studies, the 5-year survival of oropharyngeal cancer patients has been shown to be better when treated with primary surgical resection compared to primary radiation treatment \[[@CR9]--[@CR12]\]. Tschiesner et al. (2012) investigated the functional and quality of life outcomes between primary radiation and major surgical resection with free flap reconstruction in advanced head and neck cancer patients and found no significant difference \[[@CR13]\]. The past decade has seen a significant paradigm shift toward surgical treatment of OPSCC coinciding with the introduction of less invasive transoral approaches \[[@CR14], [@CR15]\]. Studies have reported excellent functions and quality of life after transoral surgery for oropharyngeal cancer patients \[[@CR15]--[@CR17]\]. In previous studies conducted by our group we have found that surgically treated oral and oropharyngeal cancer patients have excellent functional outcomes including speech intelligibility and safe efficient swallowing \[[@CR18]--[@CR21]\] but this was not investigated in relation to HPV/p16 status. Several studies have reported improved survival outcomes with HPV positive vs. negative OPSCC but there is a paucity of knowledge regarding the role of HPV positivity on functional outcomes and quality of life, particularly in surgically treated patients.

The aim of this study is to determine the impact of the p16 status on speech, swallowing and QOL outcomes in OPSCC patients treated with primary surgery.

Methods {#Sec2}
=======

Prior to commencing the study, ethical clearance was sought from the University of Alberta Health Research and Ethics Board.

Study design and patients {#Sec3}
-------------------------

The study involved a retrospective review of a prospectively collected outcomes dataset. The initial sample consisted of 226 patients with OPSCC, treated and followed in the University of Alberta Hospital from 1998 to 2009. All of these patients were treated with major resection and free flap reconstruction. As part of our standard care, patients are assessed at the visit the Institute for Reconstructive Sciences in Medicine (iRSM) at the Misericordia Hospital in Edmonton, Alberta, Canada; at 3 different times for speech, swallowing and QOL assessments with a speech-language pathologist. A retrospective chart review of these patients was completed to determine the following parameters: age, gender, risk factors, site of lesion, TNM staging and speech, swallowing and QOL data.

Subjects selection and withdrawal {#Sec4}
---------------------------------

### Inclusion criteria {#Sec5}

Adult patients (\> 18 years).Primary cancer of the oropharynx.Primary treatment was surgical.Available speech and swallowing outcomes data.Available QOL data.

### Exclusion criteria {#Sec6}

Patients younger than 18 years.Head and neck cancer other than the oropharynx.Treated primarily with radiation therapy.Speech and swallowing data not available.QOL data not available.

Functional assessment {#Sec7}
---------------------

Swallowing and speech functions and QOL were measured and prospectively recorded at 3 points in time: preoperatively, 6 months postoperative; and 1 year postoperative at the.

Head and Neck Surgery Functional Assessment Laboratory at the iRSM \[[@CR22]\].

Objective functional outcomes were measured as follows:

### Speech assessment {#Sec8}

Single Word Intelligibility (SWI) and Sentence Intelligibility (SI) as determined by Naїve listener were measured using the standard Computerized Assessment of Intelligibility of Dysarthric Speech (CAIDS; Pro-Ed, Austin, TX) \[[@CR22], [@CR23]\].

### Swallowing assessment {#Sec9}

Swallowing was assessed in terms of ability (gastrostomy tube (g-tube) requirement rate) and safety (risk of aspiration) of swallowing. Swallowing ability was defined as complete independence from a g-tube to maintain their daily caloric requirements. Video Fluoroscopic Swallowing Studies (VFSS), using a standard Penetration-Aspiration Scale \[[@CR24]\], were used to evaluate swallowing safety \[[@CR22], [@CR24]\] . Patients were divided into two groups according to the Penetration-Aspiration Scale (Aspiration group and No Aspiration group).

Quality of life (QOL) assessment {#Sec10}
--------------------------------

QOL was measured using the European Organization for Research and Treatment of Cancer Head & Neck 35 Quality of Life Questionnaire (EORTC H&N 35). Subjects were asked to fill out the questionnaire to assess their QOL, which takes 20--30 min each time. Scores were scaled up to a maximum of 100. Minimal clinically important differences were approximated as described by others \[[@CR25]\]**.**

HPV status and P16 immunohistochemistry staining {#Sec11}
------------------------------------------------

Several different methods have been developed and introduced to identify HPV status. To date viral DNA amplification by the Polymerase Chain Reaction (PCR) is still the most sensitive test \[[@CR26]--[@CR28]\]. Immunohistochemistry (IHC) using p16 has been used as a surrogate marker of oncogenic HPV and found to have a significant concordance rate of more than 80% with PCR testing and this test is now widely available and accepted as a method of detecting HPV status, and has been used in many investigational studies \[[@CR3], [@CR10], [@CR29]--[@CR31]\]. HPV status of patients in this study was determined by p16 immunohostochemistry of formalin-fixed paraffin embedded (FFPE) tumors as previously reported \[[@CR10]\]. Arrays were subjected to both a standard hematoxylin and eosin (H&E) staining and a p16INK4a mouse monoclonal antibody (p16) (Fig. [1](#Fig1){ref-type="fig"}). P16 positivity was digitally determined using AQUAnalysis software (HistoRx, Inc. Branford, Connecticut) as previously described \[[@CR10]--[@CR12], [@CR32]\].Fig. 1Histopathologic slide showing P16 positivity

Data analysis {#Sec12}
-------------

Data management and analysis was performed using SPSS version 20. A univariate comparison between the groups was made using Mann-Whitney Test for the continuous data and Chi square test for the categorical data. The Wilcoxon non-parametric test was also used to compare the data across the time periods and the Friedman test was used for the statistical analysis of QOL. The mean scores for word and sentence intelligibility were compared using linear regression analysis. A multivariate analysis of the different variables with potential effect on the rate of g-tube requirement was done using a logistic regression analysis. Differences between groups were deemed to be statistically significant with a *p* value \< 0.05.

Results {#Sec13}
=======

Patient demographics and clinical characteristics {#Sec14}
-------------------------------------------------

Table [1](#Tab1){ref-type="table"} summarizes the demographics and clinical characteristics of the 112 patients that have met the inclusion/exclusion criteria and included in this study. Similar to previous studies, the majority of OPSCC in this cohort were relatively young (mean age 56 years), p16 positive males. Most patients also presented with advanced stage disease as according the AJCC 7th edition (Table [2](#Tab2){ref-type="table"}).Table 1Demographics and clinical characteristicsCharacteristicNo. (%)*N*112Age (yrs)56Gender Male92 (82%) Female20 (18%)p16 status P16 Positive (+)63 (56%) P16 Negative (−)49 (44%)Table 2Primary Tumor StagesN0N1N2aN2bN2cN3TOTALT11 (1%)2 (2%)4 (3.5%)2 (2%)0 (0%)2 (2%)11 (10%)T21 (1%)5 (4.5%)7 (6.25%)10 (9%)2 (2%)5 (4.5%)30 (27%)T313 (12%)6 (5.4%)7 (6.25%)18 (16%)3 (2.7%)2 (2%)49 (44%)T41 (1%)5 (4.5%)3 (2.7%)5 (4.5%)7 (6.25%)1 (1%)22 (19%)TOTAL16 (14%)18 (16%)21 (19%)35 (31%)12 (11%)10 (9%)112

Functional outcome results {#Sec15}
--------------------------

### Speech function {#Sec16}

#### Single word and sentence intelligibilities {#FPar1}

The results in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} showed an 85% postoperative mean score for word intelligibility. On the other hand, showed an excellent postoperative sentence intelligibility of 95.4%. Overall, p16 status did not show any statistical significant effect on speech intelligibility.Table 3Single word intelligibilityIntelligibilityPre-Op6 Mo Post-Op12 Mo Post-OpΔ*p*-valueAll94.4%85.5%85%9.4%\< 0.001P16 -92%85.1%84.8%7.2%.003P16 +95.7%84.4%85.1%10.6%\< 0.001*p*-value (p16)0.2480.4180.795Table 4sentence intelligibilityIntelligibilityPre-Op6 Mo Post-Op12 Mo Post-OpΔ*p*-valueSentence98.7%94%95.4%3.3%\< 0.001P16-98.2%92.1%94.6%3.6%.053P16+99%95%95.8%3.2%\< 0.001*p*-value (p16)0.1440.2070.897

A Multivariable analysis using linear-regression was used to assess the effect of p16 status, age, stage and the percentage of base of tongue and soft palate resection on intelligibility. This analysis revealed a positive correlation between patients' age and the percentage of base of tongue resection on both single word and sentence intelligibilities with *p*-values less than 0.05. There were no significant differences in intelligibilities in relation to p16 status (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}).Table 5Single word intelligibility -- Multivariable analysisVariables*p-*Value95*%* confidence intervalP160.22−5.74- 13.74Increase in AGE0.040.08--0.80T Stage0.54−12.16- 11.89Table 6Sentence intelligibility -- Multivariable analysisVariables*P-*Value95*%* confidence intervalP160.86−3.95- 5.29Increase in AGE0.010.05--0.39T Stage0.56−7.58- 3.83

### Swallowing function {#Sec17}

#### Swallowing ability {#FPar2}

Only 13% of patients required a g-tube 12--months after surgery to maintain their daily caloric requirements and there was no statistical significant difference in the rate of g-tube dependency in relation to p16 status (Table [7](#Tab7){ref-type="table"}). The results, as shown in Table [8](#Tab8){ref-type="table"}, indicate that the percentage of base of tongue resection has a significant association with the rate of g-tube dependency.Table 7Swallowing Ability -- The rate of G-Tube requirementALL (% with g-tube)P16- (% with g-tube)P16 + (% with g-tube)HPV+/HPV- (*p*-Value)Pre OP2600.0686 M Post OP29.641230.08412 M Post OP11.52190.172Table 8The rate of G-Tube requirement -- Multivariable analysisVariables*P-*Valuep160.23AGE0.9T Stage0.42% BOT0.01% SP0.37Logistic regression analysis*BOT* Base of Tongue, *SP* Soft Palate

#### Swallowing safety {#FPar3}

Overall, swallowing was found to be safe post-operatively and there was no increase in the risk of aspiration was detected in relation to p16 status. None of these differences were statistically significant (Table [9](#Tab9){ref-type="table"}).Table 9Swallowing Safety (the risk (%) of aspirationAllP16-P16+*p*-ValuePre OP0%0%0%6 M Post Op11.5%17.4%8%0.2612 M Post Op12%17.6%9.4%0.4*p*-Value0.0970.2230.368Using Video Fluoroscopic Swallowing Study (VFSS) to Measure the risk of aspiration according to a standard Penetration-Aspiration Scale

Quality of life (QOL) results {#Sec18}
-----------------------------

Patients were divided into three groups according to the change in their QOL scores. Change (Δ) in mean score:Mild Δ = 5--10Moderate Δ = 10--20Severe Δ ≥ 20

What has been considered as clinically significant was mean score difference of more than 10 \[[@CR33]--[@CR35]\].

### Overall quality of life {#Sec19}

From this data, we can see that the overall QOL scores postop and preop was excellent (Tables [10](#Tab10){ref-type="table"} and [11](#Tab11){ref-type="table"}), although the difference was statistically significant, but the differences in the mean scores was not clinically significant (Δ in mean score \< 10). Figure [2](#Fig2){ref-type="fig"} presents an overview of the QOL outcomes by time frame and the main QOL domains.Table 10Quality of Life (QOL) mean ScoresPre-Op Mean score (SD)6 months Mean score (SD)12 months Mean score (SD)Δ*P-* Valuepain24 (23)22 (17.6)16 (17.3)−80.02swallowing16 (23)31 (22.6)26 (22.2)10\< 0.01senses14 (21.2)26 (20.7)21 (23.2)7\< 0.01speech15 (18.3)23 (18.7)22 (19.4)70.03social eating16 (25)28 (22.3)32 (24.3)16\< 0.01social contact5 (12.4)12 (18)11 (17.6)60.004sexuality16 (28)23 (28.1)18 (27.7)20.02teeth10 (22)14 (21.1)24 (32)140.07mouth open20 (33)39 (33)42 (36.1)22\< 0.01coughing30 (24.1)40 (28)34 (23.7)40.03felt ill12 (21.3)15 (24)5 (15.5)−70.002Table 11Overall Quality of Life (QOL) Scores*N*Mean EORTC H&N 35 score (SD)Pre-Op8519 (14.14)6 M Post-p6832 (13.47)12 M Post-p6827 (12.54)Change (Δ)178 (*p \<* 0.01)*Δ = 8 (\< 10) not clinically significant*Fig. 2Overall Quality of Life (QOL) Domains: **a**: Pain and feeling ill improved at 12 months post operatively from the base line. **b**: Impairment in social eating and minimal in social contact. **c**: Impairment compared to base line

### Quality of life *(QOL) and p16* {#Sec20}

When comparing different domains of QOL and p16 status it was found that p16 positive patients had improved social eating and sexuality compared to p16 negative patients (clinically and statistically significant) (Table [12](#Tab12){ref-type="table"}). There was no clinical significant difference in the overall QOL in relation to p16 status (Table [12](#Tab12){ref-type="table"}).Table 12p16 and Quality of Life (QOL) Scores**HPV - Mean score (SD)HPV + Mean score (SD)Δ*P-*** **Valuepain**18 (17.34)16 (17.37)- 20.58**swallowing**30 (24.22)27 (21.33)- 30.63**senses**16 (19.77)24 (24.54)80.24**speech**21 (17.78)23 (20.42)20.75**social eating**43 (31.53)26 (17.29)**- 170.04social contact**11 (17.71)11 (17.82)00.99**sexuality**28 (35.87)16.5 (22.69)**- 11.5**0.19**teeth**23 (32.46)24 (32.1)10.84**mouth open**45 (38.41)40 (35.25)- 50.64**coughing**35 (23.52)34 (24.09)- 10.89**felt ill**1.5 (6.95)7 (18.26)5.50.41**NP16 - Mean score (SD)P16 + Mean score (SD)ΔP-ValuePre-Op**8222.5 (15.6)13 (12.1)- 9.5**0.0056 M Post-p**6533.5 (16)29 (12)- 4.50.24**12 M Post-p**6528.5 (10.5)26 (13.4)- 2.50.45Significant *p*-value are highlited in bold

Discussion {#Sec21}
==========

The current literature suggests that surgical treatment of advanced oropharyngeal cancer is associated with poor QOL and functional outcomes. Results of our study suggest the contrary; these patients achieved excellent swallowing abilities with only 13% of the patients required G-Tube at 12 months post treatment, which is comparable to patients that underwent TORS \[[@CR16], [@CR36]\] and speech perception, with sentence recognition by naïve listeners that was near perfect post-surgery. Although word intelligibility is a sensitive test for speech outcome, it is not clinically important. The results shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} indicate that the mean score for postoperative word intelligibility dropped on the order of 9%. On the other hand, sentence intelligibility that is more clinically important as it represents listener appreciation of contextual speech showed only a 3% drop in intelligibility after surgery. Overall, p16 status did not affect Sentence/contextual speech. Contextual speech was still well understood in both p16 positive and p16 negative patients with no significant differences. Advanced stage OPSCC patients treated with primary surgical approaches have also been shown to have better survival outcomes, especially those in the high-risk groups (HPV negative and smokers) \[[@CR10], [@CR37]\] . Primary surgery for OPSCC can therefore provide excellent oncologic and functional outcomes.

HPV positive OPSCC is known to have excellent treatment response with high survival rates shown to extend beyond 5 years \[[@CR38]--[@CR41]\]. With the rising population of HPV-OPSCC survivors, investigating the functional outcomes and QOL of these patients is of utmost importance. To date, few studies have reported an association between HPV status and functional outcomes and/or QOL in OPSCC \[[@CR25]\]. A study of 177 OPSCC patients (45% p16 +) reported higher University of Washington (UW) QOL scores in p16 positive patients pre- and post-treatment \[[@CR42]\]. Another study using showed higher pre-treatment UW QOL scores in HPV positive vs negative OPSCC, however this association did not persist beyond 1 year post-treatment \[[@CR43]\]. In a multicenter study of 48 patients with OPSCC (39% HPV+), no significant differences in EORTC QOL surveys between HPV positive and negative patients \[[@CR44]\]. When comparing surgical versus non-surgical treatments, these studies did not show any differences in QOL measurements. In a retrospective analysis of OPSCC patients treated with CRT, p16 positive patients had better baseline QOL scores but demonstrated a greater reduction in QOL post-treatment \[[@CR45]\]. An independent study comparing TORS and CRT treatments showed that patients treated with primary TORS approaches had significantly better saliva-related QOL \[[@CR46]\]. The present study was designed to determine the association of p16 status on the functional outcomes and QOL of surgically treated OPSCC with open surgery and free flap reconstruction that is more. Our patient cohort was unique with a large number of surgically treated patients, however similar to other studies, we did not find significant differences between p16 positive and negative OPSCCs. Regardless of p16 status, surgically treated OPSCC patients had excellent QOL, speech and swallowing outcomes.

This study was limited by a lack of reliable tobacco use history available as part of our retrospective analysis. Only surgically treated patients were included in this study and therefore comparisons cannot be made with patients who received CRT or RT alone. In addition, a single instrument was used to measure QOL, however, the EORTC H&N 35 has been validated and is one of the most widely accepted QOL questionnaires for OPSCC \[[@CR25], [@CR44], [@CR47]\].

Conclusion {#Sec22}
==========

This study suggests that primary surgery for OPSCC results in excellent QOL and functional outcomes that are not associated with p16 status. Further prospective studies comparing surgical and non-surgically treated patients according to HPV/p16 status may be beneficial in predicting and optimizing outcomes.
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